The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis
Crossref DOI link: https://doi.org/10.1186/s13075-015-0651-0
Published Online: 2015-05-20
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Van Roy, Maarten
Ververken, Cedric
Beirnaert, Els
Hoefman, Sven
Kolkman, Joost
Vierboom, Michel
Breedveld, Elia
‘t Hart, Bert
Poelmans, Sofie
Bontinck, Lieselot
Hemeryck, Alex
Jacobs, Sandy
Baumeister, Judith
Ulrichts, Hans
License valid from 2015-05-20